SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

SPY is surging as market participants react to headlines regarding potential diplomatic negotiations to end the ongoing conflict in the Middle East, despite ongoing volatility in oil prices. The community remains deeply divided, with many debating whether the rally is a genuine recovery or a temporary relief pop driven by unverified news and algorithmic positioning.

Invesco QQQ Trust Series 1 - Units of beneficial interest

The market is experiencing a high-volatility relief rally driven by conflicting headlines regarding potential war de-escalation in the Middle East and end-of-quarter portfolio rebalancing. While many traders are skeptical and labeling the move a bull trap, the community remains deeply divided, with bears pointing to elevated oil prices as a sign of underlying fragility while bulls are aggressively buying the dip on expectations of institutional support.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending as investors debate whether the current price represents a deep-value buying opportunity or a signal of further downside, with the community closely tracking high short interest, institutional accumulation, and technical support levels. Despite frustration over consistent downward pressure and the recent executive transition, many long-term bulls remain focused on the company's patent portfolio, expanding enterprise partnerships, and projected growth in agentic AI.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trading higher as the market weighs escalating conflict in the Middle East and the uncertainty surrounding the Strait of Hormuz against mixed signals from U.S. leadership regarding peace negotiations. The community is sharply divided, with many traders betting on further supply shocks and potential price surges, while others view current levels as an overextended rally susceptible to sudden corrections.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors gear up for the upcoming AAD conference in Denver, where clinical data regarding its lead skin disease drug will be presented. The community is actively discussing the drug's potential for best-in-class status in treating hidradenitis suppurativa, fueling speculation around clinical breakthroughs, M&A possibilities, and potential price movement.

Spdr Dow Jones Industrial Average ETF Trust - Units of undivided interest in DIAMONDS Trust Series 1

The SPDR Dow Jones Industrial Average ETF (DIA) is experiencing heightened volatility and downward pressure as market sentiment reacts to the ongoing conflict in the Middle East and concerns over energy inflation. Community discussions are centered on the impact of shifting geopolitical news, Iranian energy infrastructure threats, and the potential for a broader economic recession, with many traders debating whether the market is reaching a capitulation point or if further declines are inevitable.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The biotech sector is experiencing significant volatility and renewed investor interest, driven by a wave of high-premium M&A activity and positive data readouts for late-stage pipeline assets. While broader market uncertainty and geopolitical concerns have created a tug-of-war in price action, the community remains intensely focused on identifying potential buyout targets and monitoring institutional accumulation patterns within small-cap biotech leaders.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSTR is facing intense volatility as market participants debate the company's aggressive dilution strategy for Bitcoin accumulation amidst broader macroeconomic concerns and recent quantum computing headlines. The community remains deeply polarized, with bulls highlighting the potential of Saylor's treasury model while bears increasingly warn of sustainability risks, dividend pressures, and potential downside price targets.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is trending as investors gear up for the upcoming release of the company's 2025 Annual Report and earnings call, which are being closely watched for signs of a turnaround. The community is actively debating the stock's potential for a squeeze, citing high short interest and a significant valuation gap compared to its underlying assets, while tracking the company's recent debt reduction efforts.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is currently under intense scrutiny as it faces a critical earnings report amid a sustained period of price decline and multi-year lows. Community discussion is sharply divided, with bulls betting on a potential turnaround driven by brand resilience and institutional buying, while bears remain focused on persistent inventory challenges, margin compression, and significant macro headwinds in key markets like China.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Drove CASI Pharmaceuticals' 24% Rise After Hours?

CASI Pharmaceuticals shares surged over 24% after hours to $0.28 despite a formal Nasdaq delisting and plans to transition to OTC Markets.read more...

<ul class="summary-bullets"><li>As a result of the delisting decision, CASI’s shares will be suspended for trading at the opening of business on Thursday.</li><li>The company stated that it does not intend to review the Nasdaq’s delisting decision.</li><li>CASI stated in its announcement that it expects the company's existing shares to be traded on the over-the-counter market operated by OTC Markets Group Inc.</li></ul>CASI Pharmaceuticals Inc. (CASI) shares tanked more than 64% in Wednesday’s opening trade after the company announced that it had received a delisting decision from the Nasdaq.CASI stated that the Nasdaq determined that the company had failed to satisfy the continued listing conditions to remain listed on the Nasdaq Stock Market.As a result of the delisting decision, CASI’s shares will be suspended for trading at the opening of business on Thursday. The company stated that it does not intend to review the Nasdaq’s delisting decision.CASI had received an extension in December 2025 to comply with the Nasdaq’s Market Value of Listed Securities (MVLS) Rule 5550(b)(2) by Feb. 17, 2026.The MVLS rule requires a company’s market capitalization to be above $35 million for 30 consecutive trading days.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/CASI">CASI Pharmaceuticals</a> trended in the ‘bullish’ territory.<h2 class="st-heading-2">Where Will CASI’s Existing Shares Be Traded Now?</h2>CASI stated in its announcement that it expects the company's existing shares to be traded on the over-the-counter market operated by OTC Markets Group Inc.However, the company said there is no guarantee that this will materialize.“The delisting from Nasdaq will have no significant impact on the Company's operations,” the company said.<h2 class="st-heading-2">What Does CASI Do?</h2>CASI is a San Francisco, California-based biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody for the treatment of organ transplant rejection and autoimmune diseases.In January, CASI announced additional data from its Phase 1 open-label study of CID-103 in adult patients with immune thrombocytopenia (ITP). The company stated that CID-103 demonstrated a manageable safety profile, with only two Grade 3 treatment-related events and no dose-limiting toxicities.Grade 3 treatment-related events are severe and medically significant, but not life-threatening adverse events.<a href="https://stocktwits.com/symbol/CASI">CASI stock</a> is down 66% year-to-date and 87% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rxrx-stock-soars-pre-market-on-q4-beat-recursion-reached-inflection-point/cZRy27nR46D">RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trading digital board showing the data on global stock market crash. | Image source: Getty Images

Why Did CASI Stock Plummet 64% Today To Hit An All-Time Low?

CASI stated the Nasdaq determined that the company had failed to satisfy the continued listing conditions to remain listed on the Nasdaq Stock Market.

Equity

Is Alkermes (ALKS) Outperforming Other Medical Stocks This Year?

Here is how Alkermes (ALKS) and CASI Pharmaceuticals Inc. (CASI) have performed compared to their sector so far this year.

Are Medical Stocks Lagging  Alkermes (ALKS) This Year?

Veeva Systems (VEEV) Surpasses Q2 Earnings and Revenue Estimates

Veeva (VEEV) delivered earnings and revenue surprises of +4.74% and +2.80%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates

VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of +43.48% and -31.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates

VAXART (VXRT) delivered earnings and revenue surprises of +22.22% and +1,206.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates

Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of +29.69% and -7.81%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates

CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of -8.85% and -79.78%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Bioventus (BVS) Misses Q2 Earnings and Revenue Estimates

Bioventus (BVS) delivered earnings and revenue surprises of -4.55% and -0.26%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing innovative therapeutics and pharmaceutical products. The firm is also involved in developing innovative therapeutics addressing cancer and other unmet medical needs for the global market. The company was founded in 1991 and is headquartered in Beijing, China.

CASI Pharmaceuticals Inc

iShares Dynamic Equity Active ETF ($BDYN)

Grayscale Bitcoin Trust ETF ($GBTC)

Destiny Tech100 Inc ($DXYZ)

Global X Defense Tech ETF ($SHLD)

The Modern Portfolio Builder. This award honors the fund that makes long-term investing easier, cheaper, or more effective for people who want to "set it and forget it."

CASI
CASI Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CASI News

CASICASI Pharmaceuticals Inc